SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta‐analysis

SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review... INTRODUCTIONAttention‐deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder seen in about 3.4% of children and adolescents worldwide (Polanczyk, Salum, Sugaya, Caye, & Rohde, ). The prevalence rate of ADHD varies from 1.0% in Germany to 7.4% in Great Britain (Štuhec, Švab, & Locatelli, ). Polanczyk et al. () found ADHD to have similar prevalence rates in Europe and North America. Dopamine is a major neurotransmitter in the pharmacological mechanisms of psychostimulants. The dopamine transporter (DAT1) is a protein encoded by SLC6A3 (located on chromosome 5p15.3). Methylphenidate (MPH) is known to improve ADHD symptoms by inhibiting the dopamine transporter responsible for dopamine reuptake from the synaptic cleft into presynaptic terminals. MPH inhibits the reuptake of monoamines, such as dopamine and noradrenaline, and increases the synaptic and extrasynaptic concentrations of these neurotransmitters (Madhusoodanan & Goia, ). Stimulation of the non‐vesicular release and inhibition of monoamine oxidase A activity have also been reported. Moreover, MPH prolongs postsynaptic and presynaptic receptor interactions (Dinis‐Oliveira, ). However, MPH is effective in about 70% of ADHD children (Bolea‐Alamañac et al., ; Hodgkins, Shaw, Coghill, & Hechtman, ). While the reasons for this response variability among patients are unclear, they are likely to be multifactorial (Adler, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Medical Genetics Wiley

SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta‐analysis

Loading next page...
 
/lp/wiley/slc6a3-polymorphism-and-response-to-methylphenidate-in-children-with-T0258O2Mc7
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1552-4841
eISSN
1552-485X
D.O.I.
10.1002/ajmg.b.32613
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAttention‐deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder seen in about 3.4% of children and adolescents worldwide (Polanczyk, Salum, Sugaya, Caye, & Rohde, ). The prevalence rate of ADHD varies from 1.0% in Germany to 7.4% in Great Britain (Štuhec, Švab, & Locatelli, ). Polanczyk et al. () found ADHD to have similar prevalence rates in Europe and North America. Dopamine is a major neurotransmitter in the pharmacological mechanisms of psychostimulants. The dopamine transporter (DAT1) is a protein encoded by SLC6A3 (located on chromosome 5p15.3). Methylphenidate (MPH) is known to improve ADHD symptoms by inhibiting the dopamine transporter responsible for dopamine reuptake from the synaptic cleft into presynaptic terminals. MPH inhibits the reuptake of monoamines, such as dopamine and noradrenaline, and increases the synaptic and extrasynaptic concentrations of these neurotransmitters (Madhusoodanan & Goia, ). Stimulation of the non‐vesicular release and inhibition of monoamine oxidase A activity have also been reported. Moreover, MPH prolongs postsynaptic and presynaptic receptor interactions (Dinis‐Oliveira, ). However, MPH is effective in about 70% of ADHD children (Bolea‐Alamañac et al., ; Hodgkins, Shaw, Coghill, & Hechtman, ). While the reasons for this response variability among patients are unclear, they are likely to be multifactorial (Adler,

Journal

American Journal of Medical GeneticsWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial